AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$15.05
0.06 (0.37%)
ā²
5d:
-4.08%
30d:
+9.69%
90d:
-7.61%
BUY
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 11, 2026
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
š” BUY OPPORTUNITY: AMRN shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
š” BUY OPPORTUNITY: AMRN shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$28.72
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$17.84
15.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $15.05, which is considered fair relative to its 30-day fair value range of $14.10 to $15.84. The stock's valuation (Forward PE: 25.5) is in line with its historical norms (26.1). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $14.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AMRN is in a downtrend. The price is currently testing key support at $14.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. However, the stock is trading significantly above the average Wall Street target of $12.00. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$14.10 -
$15.84
Company Quality Score
53/100
(HOLD)
Options IV Signal
46th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 46th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 20.3% above Wall St target ($12.00)
Fair Price Analysis
30-Day Fair Range
$14.10 -
$15.84
Current vs Fair Value
FAIR
Expected Move (7 Days)
Ā±$1.81
(12.1%)
Support & Resistance Levels
Support Level
$14.61
Resistance Level
$17.31
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
25.51
Wall Street Target
$12.00
(-20.3%)
Revenue Growth (YoY)
17.4%
Earnings Growth (YoY)
-94.2%
Profit Margin
-38.0%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
25.5 vs 26.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$14.94
(-1%)
2-Year Target
$14.84
(-1%)
3-Year Target
$14.74
(-2%)
3-Yr Target (if PE normalizes)
(PE: 26ā26)
$15.08
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.5, Growth: 168.2%)
$50.79
(+238%)
Base:
(SPY PE: 22.3, Growth: 168.2%)
$44.40
(+195%)
Bear:
(PE: 19.0, Growth: 168.2%)
$37.74
(+151%)
š”
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 25.5 to 26.1
Stabilization Target:
$15.40
(+2.3%)
PE Expansion Potential:
+2.3%
Last updated: February 04, 2026 5:50 AM ET
Data refreshes hourly during market hours. Next update: 6:50 AM
Data refreshes hourly during market hours. Next update: 6:50 AM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1146 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$139 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$333 | 68 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 62 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$118 | 66 BUY |
